Nisa Leung is a Managing Partner of Qiming Venture Partners, leading its health care investments.
She currently sits on the board of Gan & Lee Pharmaceuticals (SHSE:603087), Zai Lab (NASDAQ: ZLAB), Venus MedTech (HKSE: 2500), Nurotron, dMed, CanSino Biologics (HKSE: 6185), New Horizon Bio, Berry Oncology, Insilico Medicine among others. Her other investments include Aeonmed Medical, Berry Genomics (SZSE: 000710), CITIC Pharmaceuticals (acquired by Shanghai Pharmaceutical HKSE: 2607), Crown Bioscience (acquired by JSR Life Sciences), Novast Pharmaceuticals, Origene Technologies (acquired by VCAN Bio SHSE: 600645), Richen, Wuxi Leiming, Chain Medical Labs, MEDx, Cure Genetics, SinoCell Tech(SHSE:688520), Apollomics, Sino United, Schrödinger (NASDAQ: SDGR) and Jacobio among others.
Nisa has been recognized by the Forbes Global 100 VC Midas List in 2019 and 2020, named Top 3 Best Female Venture Capitalist in China by Forbes in 2018 and won Venture Capital Professional of the Year by Asian Venture Capital Journal in 2017.
She is currently a visiting lecturer at Harvard Law School, a founding vice chair of PhIRDA Investment Committee, Committee member of Hong Kong Innovation and Technology Development and Re-Industrialization and member of Stanford Graduate School of Business Advisory Council. She also serves on the Board of Trustees of the Hotchkiss School and is a board member of the Hong Kong Palace Museum.
Prior to joining Qiming, she was co-founder of Biomedic Holdings with operations and investments in medical devices, pharmaceuticals and health care services in China including Novamed Pharmaceuticals (acquired by SciClone NASDAQ: SCLN), U-Systems (acquired by GE Healthcare). Nisa was Venture Partner of PacRim Ventures in Menlo Park and was previously with Softbank/Mobius Venture Capital.
Nisa earned her MBA from Stanford Graduate School of Business and a BS from Cornell University.